Home » Stocks » MYOK

MyoKardia, Inc. (MYOK)

Nov 16, 2020 - MYOK was delisted after being acquired by BMY
Stock Price: $224.91 USD 0.00 (0.00%)
Updated Nov 17, 2021 4:00 PM EST
Market Cap 11.99B
Revenue (ttm) 12.40M
Net Income (ttm) -276.96M
Shares Out 53.10M
EPS (ttm) -5.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Nov 17, 2021
Last Price $224.91
Previous Close $224.91
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 224.52 - 225.00
Day's Volume 0
52-Week Range 42.65 - 225.00

News

Hide News
The Motley Fool - 3 months ago

The deal was a big bet on one promising pipeline drug.

Other stocks mentioned: BMY
GlobeNewsWire - 3 months ago

EXPLORER -HCM Cardiac Imaging Data Presented at AHA 2020 Scientific Session with Simultaneous Publication in Circulation

GlobeNewsWire - 3 months ago

ECHO Data from EXPLORER-HCM Show Mavacamten Treatment Improved Cardiac Structure and Mitral Valve Function in Obstructive Hypertrophic Cardiomyopathy Patients

GlobeNewsWire - 3 months ago

Registry to Enable Prospective Safety Study “DISCOVER-HCM” to Track Long-Term Safety and Effectiveness of Mavacamten in Patients with Symptomatic, Obstructive Hypertrophic Cardiomyopathy Regis...

GlobeNewsWire - 3 months ago

Acquisition of MyoKardia by Bristol-Myers Squibb Expected to Close During 4th Quarter of 2020 Acquisition of MyoKardia by Bristol-Myers Squibb Expected to Close During 4th Quarter of 2020

GlobeNewsWire - 3 months ago

BRISBANE, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced three awardees of the 2020 MyoSeeds™ Research Grant Program, who have been selected to receiv...

Business Wire - 3 months ago

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced the expiration of the waiting period under the Hart-Scott-Rodi...

Other stocks mentioned: BMY
GlobeNewsWire - 3 months ago

EXPLORER Cardiac MRI Substudy Selected as Featured Scientific Presentation EXPLORER Cardiac MRI Substudy Selected as Featured Scientific Presentation

Seeking Alpha - 3 months ago

MYOK may have seemed an expensive and unwanted use of cash at first, but it couldn't have been too bad for management to have bought it. Indeed, successfully raising clinical awareness for HCM...

Other stocks mentioned: BMY
Insider Monkey - 3 months ago

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another...

PRNewsWire - 4 months ago

NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: MyoKardia, Inc. (NASDAQ: MYOK) concerning potential violations of th...

PRNewsWire - 4 months ago

NEW YORK, Oct. 8, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New...

The Motley Fool - 4 months ago

Cardiovascular drugs have been unsuccessful investments in recent years, but this one makes sense.

Other stocks mentioned: BMY
Benzinga - 4 months ago

Myokardia Inc (NASDAQ: MYOK) announced Monday a definitive agreement to be bought by Bristol-Myers Squibb Co (NYSE: BMY). The Myokardia Analysts: Wedbush analyst David Nierengarten downgraded ...

Other stocks mentioned: BMY
Zacks Investment Research - 4 months ago

After a relatively dull first half of 2020, M&A activity in the drug and biotech sector seems to be picking up in the second half of 2020.

Other stocks mentioned: BMY
PRNewsWire - 4 months ago

NEW YORK, Oct. 5, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of MyoKardia, Inc. ("MYOK" or the...

CNBC - 4 months ago

"MyoKardia is an important company because they developed a really interesting approach to the treatment of cardiovascular disease," Bristol-Myers Squibb CEO Giovanni Caforio said.

Other stocks mentioned: BMY
CNBC Television - 4 months ago

Bristol-Myers Squibb CEO on $13 billion MyoKardia acquisition: 'potentially revolutionary medicine'

"MyoKardia is an important company" with an "interesting approach to the treatment of cardiovascular disease, which is a precision approach," Bristol-Myers Squibb CEO Giovanni Caforio said.

Other stocks mentioned: BMY
Business Wire - 4 months ago

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of MyoKardia, Inc. (NASDAQ: MYOK) to Bristol-Myers Squibb Company for $225.50 ...

InvestorPlace - 4 months ago

MyoKardia's major, $13.1 billon deal with fellow pharmaceutical company Bristol Myers Squibb sent MYOK stock soaring on Monday. The post M&A News: MyoKardia (MYOK) Stock Soars on Bristol Myers...

Other stocks mentioned: BMY
The Motley Fool - 4 months ago

The transaction will give Bristol Myers Squibb a potential first-in-class cardiovascular drug with blockbuster expectations.

Other stocks mentioned: BMY
Zacks Investment Research - 4 months ago

Bristol Myers (BMY) offers $13.1 billion to acquire MyoKardia for diversifying its cardiovascular product portfolio. The transaction is expected to close in the fourth quarter of 2020.

Other stocks mentioned: BMY
Newsfile Corp - 4 months ago

New York, New York--(Newsfile Corp. - October 5, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orde...

Other stocks mentioned: BMY
24/7 Wall Street - 4 months ago

MyoKardia Inc. (NASDAQ: MYOK) shares hit an all-time high early on Monday after it was announced that Bristol-Myers Squibb Co.

Other stocks mentioned: BMY
Investors Business Daily - 4 months ago

Bristol Myers Squibb said it reached an agreement to acquire MyoKardia for $13.1 billion, adding to its portfolio of treatments for cardiovascular diseases but sending BMY stock down early. Th...

Other stocks mentioned: BMY
The Motley Fool - 4 months ago

The heart disease specialist fetches a rather rich buyout offer from Bristol Myers Squibb.

Benzinga - 4 months ago

Pharma giant Bristol-Myers Squibb Co (NYSE: BMY) is bulking up, as the company announced a multi-billion dollar deal to buy cardio-focused biopharma Myokardia Inc (NASDAQ: MYOK). Deal Terms: B...

Other stocks mentioned: BMY
Invezz - 4 months ago

In an announcement on Monday, Bristol Myers Squibb Co (NYSE: BMY) said it will invest £10 billion to acquire MyoKardia Inc (Nasdaq: MYOK). The deal, it added, will help it expand its footprint...

Other stocks mentioned: BMY
PRNewsWire - 4 months ago

SAN DIEGO, Oct. 5, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of MyoKardia, Inc. ("MyoKardia" or the "Com...

Reuters - 4 months ago

Bristol Myers Squibb Co said on Monday it would buy MyoKardia Inc for about $13 billion to bolster its portfolio of heart disease treatments, as it seeks to reduce some of its dependence on ca...

Other stocks mentioned: BMY
Market Watch - 4 months ago

Shares of MyoKardia Inc. MYOK, -0.36% soared 57% toward a record high in premarket trading Monday, after the biotechnology company confirmed that it agreed to be bought out by Bristol Myers Sq...

Other stocks mentioned: BMY
Business Wire - 4 months ago

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced a definitive merger agreement under which Bristol Myers Squibb...

Other stocks mentioned: BMY
GlobeNewsWire - 5 months ago

BRISBANE, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the first patient has been dosed in the company’s Phase 2 clinical trial of danicamti...

CNBC Television - 5 months ago

Myokardia CEO talk about its new trial data to treat heart disease

Myokardia develops therapies and treatments for inherited heart conditions, particularly hypertrophic cardiomyopathy or HCM, which affects 650,000 people in the U.S.

GlobeNewsWire - 5 months ago

EXPLORER-HCM Data Presented During Live Hot Line Session at ESC Congress 2020 with Simultaneous Publication in The Lancet

Kiplinger - 6 months ago

It's not uncommon for stocks that have significantly outperformed for several months to take a breather.

Other stocks mentioned: ALLO, DKNG, PLUG, UTHR, XLRN, YY
GlobeNewsWire - 6 months ago

Near-Term Focus on Pursuing Approval of Mavacamten for Obstructive HCM

GlobeNewsWire - 6 months ago

Virtual Analyst and Investor Event to Review Data Planned for 8:00 a.m. EDT on August 31 Virtual Analyst and Investor Event to Review Data Planned for 8:00 a.m. EDT on August 31

GlobeNewsWire - 6 months ago

BRISBANE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that Jake Bauer, Chief Business Officer, will present at the 2020 Wedbush PacGrow Healthcar...

Seeking Alpha - 6 months ago

MyoKardia, Inc. (MYOK) CEO Tassos Gianakakos on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

BRISBANE, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the second quarter ended June 30, 2020.

GlobeNewsWire - 6 months ago

VALOR-HCM Designed to Generate Direct Evidence of Improved Outcomes for People with HCM by Reducing the Need for Invasive Septal Reduction Therapy VALOR-HCM Designed to Generate Direct Evidenc...

GlobeNewsWire - 6 months ago

VALOR-HCM Designed to Generate Direct Evidence of Improved Outcomes for People with HCM by Reducing the Need for Invasive Septal Reduction Therapy VALOR-HCM Designed to Generate Direct Evidenc...

GlobeNewsWire - 6 months ago

BRISBANE, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will report second quarter financial and operating results on Tuesday, August 4, 2...

GlobeNewsWire - 7 months ago

BRISBANE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designati...

GlobeNewsWire - 7 months ago

BRISBANE, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced the appointment of Denelle Waynick as General Counsel and Corporate Secretary. Ms. Waynick ...

Seeking Alpha - 8 months ago

MyoKardia's Positive Data And Other News: The Good, Bad And Ugly Of Biopharma

GlobeNewsWire - 8 months ago

Danicamtiv was Well Tolerated;  Demonstrated Improvements in Cardiac Contractility and Preserved Diastolic Function in Patients with Stable Heart Failure with Reduced Ejection Fraction

GlobeNewsWire - 8 months ago

-- MyoKardia to Host Conference Call at 8:30 a.m. ET on Monday, June 22, 2020 -- BRISBANE, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that dat...

GlobeNewsWire - 8 months ago

BRISBANE, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the...

About MYOK

MyoKardia, a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyo... [Read more...]

Industry
Biotechnology
IPO Date
Oct 29, 2015
CEO
Anastasios E. Gianakakos
Employees
318
Stock Exchange
NASDAQ
Ticker Symbol
MYOK
Full Company Profile

Financial Performance

Financial Statements